Search results
Showing 346 to 360 of 2172 results for technology appraisal
NICE is unable to make a recommendation on trastuzumab deruxtecan (Enhertu) for treating hormone receptor-positive HER2-low metastatic breast cancer in adults after 2 or more endocrine treatments. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1112
Mirikizumab for previously treated moderately to severely active Crohn's disease (TA1080)
Evidence-based recommendations on mirikizumab (Omvoh) for previously treated moderately to severely active Crohn's disease in adults.
NICE is unable to make a recommendation about the use in the NHS of bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer. This is because Roche did not provide an evidence submission.
Show all sections
Sections for TA560
Evidence-based recommendations on olaparib (Lynparza) for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer in adults.
NICE is unable to make a recommendation on ramucirumab (Cyramza) with erlotinib for untreated epidermal growth factor receptor (EGFR)-positive metastatic non-small-cell lung cancer. This is because Eli Lilly and Company Limited did not provide an evidence submission.
Show all sections
Sections for TA635
Trifluridine–tipiracil for previously treated metastatic colorectal cancer (TA405)
Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) for previously treated metastatic colorectal cancer in adults.
NICE is unable to make a recommendation about the use in the NHS of niraparib (Zejula) with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer in adults. This is because Johnson & Johnson Innovative Medicine did not provide an evidence submission.
Show all sections
Sections for TA1032
Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C (TA365)
Evidence-based recommendations on ombitasvir–paritaprevir–ritonavir (also known as Viekirax) with or without dasabuvir (also known as Exviera) for adults with some types (called genotypes) of chronic hepatitis C.
In development Reference number: GID-TA11220 Expected publication date: TBC
NICE is unable to make a recommendation about the use in the NHS of pembrolizumab (Keytruda) for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy. This is because Merck Sharp & Dohme UK Ltd did not provide an evidence submission
Show all sections
Sections for TA570
NICE is unable to make a recommendation about the use in the NHS of atezolizumab (Tecentriq) for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable in adults. This is because Roche Products did not provide an evidence submission.
Show all sections
Sections for TA1047
Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA733)
Evidence-based recommendations on inclisiran (Leqvio) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.
NICE is unable to make a recommendation on adagrasib (Krazati) for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer in adults. This is because Bristol Myers Squibb will consider restarting this evaluation when the final overall survival analysis can be included in the economic model.
Show all sections
Sections for TA1076
Evidence-based recommendations on aflibercept (Eylea) for treating sight problems caused by diabetic macular oedema in adults.
Paclitaxel + XR17 (Paclical) with carboplatin for ovarian cancer [TSID5462]
Topic prioritisation